The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
|Articles|October 1, 2002
New strategies improve success of oral ED therapy
Orlando, FL-Men with erectile dysfunction who fail initial treatment with sildenafil citrate (Viagra) are seeing varying degrees of improvement when therapy is supplemented with other agents, vacuum devices, or education and counseling.
Advertisement
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
5